

**Comparison of Medicare Drug Payments Between Quarter 2 and Quarter 3 2005**

HCPCS	Name	Unit	2004 Payment for Office-Administered Drugs	Q2 2005 Payment for Office-Administered Drugs (ASP + 6%)	Q3 2005 Payment for Office-Administered Drugs (ASP + 6%)	Percent Change from Q2 2005 to Q3 2005
J0128	Injection, abarelix	10 mg	**	\$65.74	\$67.89	3.3%
J0640	Injection, leucovorin calcium	50 mg	\$3.00	\$1.27	\$1.30	2.4%
J0696	Injection, ceftriaxone sodium	250 mg	\$13.35	\$6.71	\$6.80	1.3%
J0780	Injection, prochlorperazine	up to 10 mg	\$3.74	\$3.65	\$2.97	-18.6%
J0880	Injection, darbepoetin alfa	5 mcg	\$21.20	\$16.12	\$15.30	-5.1%
J1094	Injection, dexamethasone acetate	1 mg	\$0.64	\$0.33	\$0.60	81.8%
J1100	Injection, dexamethasone sodium phosphate	1 mg	\$0.10	\$0.15	\$0.12	-20.0%
J1200	Injection, diphenhydramine HCl	up to 50 mg	\$1.43	\$0.58	\$0.88	51.7%
J1260	Injection, dolasetron mesylate	10 mg	\$13.85	\$6.43	\$6.32	-1.7%
J1440	Injection, filgrastim (G-CSF)	300 mcg	\$158.50	\$175.14	\$175.26	0.1%
J1441	Injection, filgrastim (G-CSF)	480 mcg	\$267.79	\$277.15	\$277.02	0.0%
J1563	Injection, immune globulin, intravenous	1 g	\$66.00	**		
J1564	Injection, immune globulin	10 mg	\$0.72	**		
J1626	Injection, granisetron HCl	100 mcg	\$15.62	\$7.11	\$7.15	0.6%
J1645	Injection, dalteparin sodium	2500 IU	\$14.04	\$10.20	\$11.00	7.8%
J1650	Injection, enoxaparin sodium	10 mg	\$5.46	\$5.19	\$5.34	2.9%
J1655	Injection, tinzaparin sodium	1000 IU	\$3.43	\$2.48	\$2.57	3.6%
J1750	Injection, iron dextran	50 mg	\$16.03	\$11.22	\$11.22	0.0%
J1956	Injection, levofloxacin	250 mg	\$18.62	\$8.09	\$7.80	-3.6%
J2060	Injection, lorazepam	2 mg	\$2.81	\$1.41	\$1.47	4.3%
J2353	Injection, octreotide depot	1 mg	\$77.14	\$85.81	\$86.89	1.3%
J2354	Injection, octreotide, non-depot	25 mcg	\$3.81	\$4.59	\$4.88	6.3%
J2355	Injection, oprelvekin	5 mg	\$239.67	\$244.52	\$245.11	0.2%
J2405	Injection, ondansetron HCl	1 mg	\$5.58	\$3.73	\$3.69	-1.1%
J2430	Injection, pamidronate disodium	30 mg	\$237.88	\$57.35	\$50.40	-12.1%
J2505	Injection, pegfilgrastim	6 mg	\$2,507.50	\$2,138.60	\$2,087.70	-2.4%
J2550	Injection, promethazine HCl	up to 50 mg	\$2.55	\$2.23	\$2.15	-3.6%
J2765	Injection, metoclopramide HCl	up to 10 mg	\$1.67	\$0.42	\$0.47	11.9%
J2780	Injection, ranitidine HCl	25 mg	\$1.29	\$0.95	\$0.83	-12.6%
J2792	Rho(D) immune globulin h, sd	100 IU	\$18.39	\$11.82	\$10.01	-15.3%
J2820	Injection, sargramostim (GM-CSF)	50 mcg	\$24.47	\$20.72	\$22.88	10.4%
J2916	Injection, sodium ferric gluconate complex in sucrose injection	12.5 mcg	\$7.31	\$4.73	\$4.71	-0.4%
J3487	Injection, zoledronic acid	1 mg	\$194.54	\$198.72	\$198.50	-0.1%
J7030	Infusion, normal saline solution	1000 cc	\$8.89	\$0.98	\$1.02	4.1%
J7040	Infusion, normal saline solution, sterile	500 cc	\$5.64	\$0.49	\$0.51	4.1%
J7042	5% dextrose/normal saline	500 ml	\$8.45	\$0.37	\$0.37	0.0%
J7050	Infusion, normal saline solution	250 cc	\$2.22	\$0.25	\$0.26	4.0%
J7060	5% dextrose/water	500 ml	\$8.09	\$1.13	\$1.13	0.0%
J9000	Doxorubicin HCl	10 mg	\$8.16	\$5.39	\$5.92	9.8%
J9001	Doxorubicin HCl, all lipid formula	10 mg	\$352.06	\$358.98	\$359.36	0.1%
J9010	Alemtuzumab	10 mg	\$523.00	\$507.45	\$511.60	0.8%
J9015	Aldesleukin	single use vial	\$657.15	\$688.98	\$693.78	0.7%
J9017	Arsenic trioxide	1 mg	\$32.94	\$33.15	\$33.26	0.3%
J9020	Asparaginase	10,000 units	\$56.02	\$54.41	\$54.30	-0.2%
J9031	BCG live (intravesical), per instillation	1 each	\$143.28	\$119.53	\$113.57	-5.0%
J9035	Injection, bevacizumab	10 mg	**	\$57.11	\$57.10	0.0%
J9040	Bleomycin sulfate	15 units	\$150.61	\$53.19	\$37.57	-29.4%
J9041	Injection, bortezomib	0.1 mg	**	\$28.38	\$29.01	2.2%
J9045	Carboplatin	50 mg	\$135.15	\$75.75	\$52.18	-31.1%
J9050	Carmustine	100 mg	\$121.84	\$138.71	\$138.49	-0.2%
J9055	Injection, cetuximab	10 mg	**	\$49.66	\$49.64	0.0%
J9060	Cisplatin, powder or solution	10 mg	\$13.56	\$4.25	\$2.97	-30.1%
J9062	Cisplatin	50 mg	\$67.79	\$21.23	\$14.84	-30.1%
J9065	Injection, cladribine	1 mg	\$45.90	\$38.66	\$37.25	-3.6%
J9070	Cyclophosphamide	100 mg	\$5.13	\$1.90	\$2.15	13.2%
J9080	Cyclophosphamide	200 mg	\$9.74	\$3.81	\$4.31	13.1%

**Comparison of Medicare Drug Payments Between Quarter 2 and Quarter 3 2005**

HCPCS	Name	Unit	2004 Payment for Office-Administered Drugs	Q2 2005 Payment for Office-Administered Drugs (ASP + 6%)	Q3 2005 Payment for Office-Administered Drugs (ASP + 6%)	Percent Change from Q2 2005 to Q3 2005
J9090	Cyclophosphamide	500 mg	\$20.45	\$10.30	\$15.20	47.6%
J9091	Cyclophosphamide	1 g	\$40.92	\$19.03	\$21.53	13.1%
J9092	Cyclophosphamide	2 g	\$81.82	\$38.06	\$43.07	13.2%
J9093	Cyclophosphamide, lyophilized	100 mg	\$5.21	\$0.24	\$0.73	204.2%
J9094	Cyclophosphamide, lyophilized	200 mg	\$10.41	\$0.48	\$1.45	202.1%
J9095	Cyclophosphamide, lyophilized	500 mg	\$20.45	\$1.19	\$1.81	52.1%
J9096	Cyclophosphamide, lyophilized	1 g	\$40.92	\$2.39	\$3.64	52.3%
J9097	Cyclophosphamide, lyophilized	2 g	\$83.95	\$4.77	\$3.64	-23.7%
J9098	Cytarabine liposome	10 mg	\$332.35	\$359.36	\$383.29	6.7%
J9100	Cytarabine	100 mg	\$7.33	\$1.65	\$1.02	-38.2%
J9110	Cytarabine	500 mg	\$7.65	\$8.24	\$5.08	-38.3%
J9120	Dactinomycin	0.5 mg	\$12.41	\$12.04	\$12.02	-0.2%
J9130	Dacarbazine	100 mg	\$10.04	\$6.09	\$4.94	-18.9%
J9140	Dacarbazine	200 mg	\$19.47	\$12.18	\$9.87	-19.0%
J9150	Daunorubicin HCl	10 mg	\$66.42	\$34.64	\$25.15	-27.4%
J9151	Daunorubicin citrate, liposomal formulation	10 mg	\$57.80	\$56.51	\$56.51	0.0%
J9160	Denileukin diftitox	300 mcg	\$1,190.85	\$1,212.83	\$1,243.93	2.6%
J9170	Docetaxel	20 mg	\$301.40	\$295.69	\$295.27	-0.1%
J9178	Injection, epirubicin HCl	2 mg	\$24.73	\$24.69	\$24.60	-0.4%
J9181	Etoposide	10 mg	\$1.53	\$0.73	\$0.49	-32.9%
J9182	Etoposide	100 mg	\$15.30	\$7.31	\$4.89	-33.1%
J9185	Fludarabine phosphate	50 mg	\$318.59	\$257.63	\$246.83	-4.2%
J9190	Fluorouracil	500 mg	\$1.85	\$1.85	\$1.41	-23.8%
J9200	Floxuridine	500 mg	\$122.40	\$59.07	\$63.13	6.9%
J9201	Gemcitabine HCl	200 mg	\$111.33	\$115.31	\$115.22	-0.1%
J9202	Goserelin acetate implant	3.6 mg	\$375.99	\$192.68	\$185.20	-3.9%
J9206	Irinotecan	20 mg	\$130.24	\$126.73	\$126.90	0.1%
J9208	Ifosfamide	1 g	\$134.55	\$52.56	\$47.13	-10.3%
J9209	Mesna	200 mg	\$31.45	\$13.43	\$12.98	-3.4%
J9211	Idarubicin HCl	5 mg	\$375.73	\$308.28	\$327.55	6.3%
J9212	Injection, interferon Alfacon-1, recombinant	1 mcg	\$3.67	\$3.83	\$3.92	2.3%
J9213	Injection, interferon alfa-2a, recombinant	3 million units	\$31.21	\$31.17	\$32.03	2.8%
J9214	Interferon alfa-2b, recombinant	1 million units	\$13.31	\$12.98	\$13.26	2.2%
J9215	Interferon alfa-N3, (human leukocyte derived)	250,000 IU	\$7.03	\$8.60	\$8.60	0.0%
J9216	Interferon gamma-1B	3 million units	\$187.19	\$272.43	\$272.44	0.0%
J9217	Leuprolide acetate (for depot suspension)	7.5 mg	\$500.58	\$226.66	\$229.85	1.4%
J9218	Leuprolide acetate	1 mg	\$23.26	\$10.76	\$9.36	-13.0%
J9219	Leuprolide acetate implant	65 mg	\$4,831.40	\$2,220.98	\$2,314.14	4.2%
J9230	Mechlorethamine HCl, (nitrogen mustard)	10 mg	\$10.74	\$10.44	\$10.42	-0.2%
J9245	Injection, melphalan HCl	50 mg	\$375.88	\$513.69	\$753.65	46.7%
J9250	Methotrexate sodium	5 mg	\$0.35	\$0.27	\$0.39	44.4%
J9260	Methotrexate sodium	50 mg	\$4.25	\$2.66	\$3.84	44.4%
J9263	Oxaliplatin	0.5 mg	\$8.45	\$8.25	\$8.29	0.5%
J9265	Paclitaxel	30 mg	\$138.28	\$18.77	\$14.78	-21.3%
J9266	Pegaspargase	single dose vial	\$1,277.13	\$1,499.31	\$1,611.20	7.5%
J9268	Pentostatin	10 mg	\$1,644.27	\$1,834.86	\$1,835.02	0.0%
J9270	Plicamycin	2.5 mg	\$83.93	\$78.99	\$78.99	0.0%
J9280	Mitomycin	5 mg	\$57.12	\$25.88	\$21.17	-18.2%
J9290	Mitomycin	20 mg	\$185.64	\$74.61	\$84.69	13.5%
J9291	Mitomycin	40 mg	\$255.00	\$144.92	\$169.38	16.9%
J9293	Injection, mitoxantrone HCl	5 mg	\$321.52	\$323.68	\$323.75	0.0%
J9300	Gemtuzumab ozogamicin	5 mg	\$1,953.94	\$2,204.14	\$2,226.82	1.0%
J9305	Injection, pemetrexed	10 mg	**	\$40.54	\$40.45	-0.2%
J9310	Rituximab	100 mg	\$438.38	\$439.81	\$455.92	3.7%
J9320	Streptozocin	1 g	\$126.58	\$150.53	\$152.59	1.4%
J9340	Thiotepa	15 mg	\$83.73	\$43.74	\$45.06	3.0%

**Comparison of Medicare Drug Payments Between Quarter 2 and Quarter 3 2005**

HCPCS	Name	Unit	2004 Payment for Office-Administered Drugs	Q2 2005 Payment for Office-Administered Drugs (ASP + 6%)	Q3 2005 Payment for Office-Administered Drugs (ASP + 6%)	Percent Change from Q2 2005 to Q3 2005
J9350	Topotecan	4 mg	\$706.17	\$741.74	\$755.74	1.9%
J9355	Trastuzumab	10 mg	\$52.01	\$52.99	\$53.93	1.8%
J9357	Valrubicin, intravesical	200 mg	\$471.24	\$369.60	\$369.60	0.0%
J9360	Vinblastine sulfate	1 mg	\$2.81	\$1.01	\$0.86	-14.9%
J9370	Vincristine sulfate	1 mg	\$30.40	\$2.96	\$2.59	-12.5%
J9375	Vincristine sulfate	2 mg	\$60.81	\$5.93	\$5.18	-12.6%
J9380	Vincristine sulfate	5 mg	\$152.02	\$15.44	\$12.96	-16.1%
J9390	Vinorelbine tartrate	10 mg	\$76.19	\$61.70	\$43.19	-30.0%
J9395	Injection, Fulvestrant	25 mg	\$81.57	\$81.39	\$81.30	-0.1%
J9600	Porfimer sodium	75 mg	\$2,329.60	\$2,413.20	\$2,150.25	-10.9%
J9999	Paclitaxel protein-bound particles (Abraxane)	1 mg	**	\$8.44	\$8.44	0.0%
Q0136	Injection, epoetin alpha, (for non ESRD use)	1000 units	\$11.62	\$9.81	\$9.49	-3.3%
Q0137	Injection, darbepoetin alfa (non-ESRD)	1 mcg	\$4.24	\$3.22	\$3.06	-5.0%
Q3025	IM injection, interferon beta 1-a	11 mcg	\$80.22	\$87.48	\$90.37	3.3%
Q9941	IVIG lyophil 1G	1 g	\$66.00	\$38.74	\$42.04	8.5%
Q9942	IVIG lyophil 10 mg	10 mg	\$0.72	\$0.39	\$0.42	7.7%
Q9943	IVIG non-lyophil 1G	1 g	\$66.00	\$56.22	\$55.93	-0.5%
Q9944	IVIG non-lyophil 10 mg	10 mg	\$0.72	\$0.56	\$0.56	0.0%

\* highlighted rows reflect Q2 price corrections issued as of 5/12/05 that apply to the entire quarter (previously paid claims must be resubmitted to obtain higher payment amounts)

\*\* no payment information available